Back to search
FDAFDA · Food and drugs·Recall number D-1073-2023

ePHEDrine in 0.9% sodium chloride, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1

Published August 9, 2023 · Recall initiated: July 17, 2023

Summary

FDA records drug Class II recall D-1073-2023, published August 9, 2023 and initiated July 17, 2023. Recalling firm: Central Admixture Pharmacy Services Inc; Status: Terminated; Reported quantity: 8,942 syringes; Lot: Lot: 17-270545, Exp. 7/16/2023; 17-270614, Exp. 7/17/2023; 17-270885, 17-270897, Exp. 7/20/2023; 17-270980, 17-270992, Exp. 7/23/2023; 17-271268, Exp. 7/26/2023; 17-271338, Exp. 7/27/2023; 17-271426, 17-271428, Exp. 7/30/2023; 17-271691, Exp. 8/2/2023; 17-271843, Exp. 8/6/2023; 17-271963, Exp. 8/8/2023; 17-272136, Exp. 8/10/2023; 17-272215, Exp. 8/13/2023; 17-272304, Exp. 8/14/2023; 17-272379, Exp. 8/15/2023; 17-272462, Exp. 8/16/2023; 17-272641, Exp. 8/20/2023; 17-272698, Exp. 8/21/2023; 17-273602, 17-273627, Exp. 9/5/2023; 17-273883, Exp. 9/10/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility: Lack of validation data for sanitization cycles

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Central Admixture Pharmacy Services Inc
Distributor
Nationwide in the USA
Lot
Lot: 17-270545, Exp. 7/16/2023; 17-270614, Exp. 7/17/2023; 17-270885, 17-270897, Exp. 7/20/2023; 17-270980, 17-270992, Exp. 7/23/2023; 17-271268, Exp. 7/26/2023; 17-271338, Exp. 7/27/2023; 17-271426, 17-271428, Exp. 7/30/2023; 17-271691, Exp. 8/2/2023; 17-271843, Exp. 8/6/2023; 17-271963, Exp. 8/8/2023; 17-272136, Exp. 8/10/2023; 17-272215, Exp. 8/13/2023; 17-272304, Exp. 8/14/2023; 17-272379, Exp. 8/15/2023; 17-272462, Exp. 8/16/2023; 17-272641, Exp. 8/20/2023; 17-272698, Exp. 8/21/2023; 17-273602, 17-273627, Exp. 9/5/2023; 17-273883, Exp. 9/10/2023.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ePHEDrine in 0.9% sodium chloride, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1 recalled?

Yes. FDA published recall D-1073-2023 on August 9, 2023. Reported hazard: Lack of assurance of sterility: Lack of validation data for sanitization cycles

What should I do if I have this product?

Voluntary: Firm initiated · Letter